Outcome of pseudomyxoma peritonei (PMP) after ytoreductive surgery (CRS) and hypertermic intraperitoneal chemotherapy (HIPEC) is heterogeneous even after adjusting for clinico-pathological prognostic variables. The identification of additional prognostic or even predictive biomarkers is an unmet clinical need. Forty patients with mucinous appendiceal tumors and PMP were clinically eligible and had evaluable tumor samples obtained after CRS and HIPEC. We carried out next-generations sequencing (NGS) of 50 gene's hotspot regions contained in the Hotspot Cancer Panel v2 using the Ion Torrent Personal Genome Machine platform (Life Technologies). KRAS and GNAS mutations were found in 72% and 52%, and their allelic frequency was below 10% in 55% and 43% of samples, respectively. KRAS and GNAS mutations were associat 0.006 and 0.011, respectively). At multivariate analysis, only KRAS mutated with worse progression-free survival (PFS) at univariate analysis (P =ions were independently associated with PFS (P = 0.012); GNAS mutations were not-being significantly associated with other poor prognostic features such as incomplete cytoreduction or KRAS mutations. Validation of results was carried out in an independent bi-institutional cohort of 25 patients and the prognostic effect of KRAS mutations was again confirmed in the multivariate model (P = 0.029). NGS approach allowed the discovery of other potentially druggable mutations such as those in PI3K, AKT, LKB1, FGFR3 and PDGFRA. Given the homogeneity of this series and the sensitivity of NGS in this low-cellularity tumor, we demonstrated for the first time a poor prognostic role of KRAS mutations.

Toward the molecular dissection of peritoneal pseudomyxoma / F. Pietrantonio, F. Perrone, A. Mennitto, E.M. Gleeson, M. Milione, E. Tamborini, A. Busico, G. Settanni, R. Berenato, M. Caporale, F. Morano, I. Bossi, A. Pellegrinelli, M. Di Bartolomeo, F. de Braud, D. Baratti, W.B. Bowne, S. Kusamura, M. Deraco. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 27:11(2016 Nov), pp. 2097-2103. [10.1093/annonc/mdw314]

Toward the molecular dissection of peritoneal pseudomyxoma

F. Pietrantonio;F. Perrone;A. Mennitto;I. Bossi;A. Pellegrinelli;F. de Braud;
2016-11

Abstract

Outcome of pseudomyxoma peritonei (PMP) after ytoreductive surgery (CRS) and hypertermic intraperitoneal chemotherapy (HIPEC) is heterogeneous even after adjusting for clinico-pathological prognostic variables. The identification of additional prognostic or even predictive biomarkers is an unmet clinical need. Forty patients with mucinous appendiceal tumors and PMP were clinically eligible and had evaluable tumor samples obtained after CRS and HIPEC. We carried out next-generations sequencing (NGS) of 50 gene's hotspot regions contained in the Hotspot Cancer Panel v2 using the Ion Torrent Personal Genome Machine platform (Life Technologies). KRAS and GNAS mutations were found in 72% and 52%, and their allelic frequency was below 10% in 55% and 43% of samples, respectively. KRAS and GNAS mutations were associat 0.006 and 0.011, respectively). At multivariate analysis, only KRAS mutated with worse progression-free survival (PFS) at univariate analysis (P =ions were independently associated with PFS (P = 0.012); GNAS mutations were not-being significantly associated with other poor prognostic features such as incomplete cytoreduction or KRAS mutations. Validation of results was carried out in an independent bi-institutional cohort of 25 patients and the prognostic effect of KRAS mutations was again confirmed in the multivariate model (P = 0.029). NGS approach allowed the discovery of other potentially druggable mutations such as those in PI3K, AKT, LKB1, FGFR3 and PDGFRA. Given the homogeneity of this series and the sensitivity of NGS in this low-cellularity tumor, we demonstrated for the first time a poor prognostic role of KRAS mutations.
GNAS; KRAS; prognosis; pseudomyxoma peritonei
Settore MED/06 - Oncologia Medica
8-ago-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
Ann Oncol-2016-Pietrantonio-annonc_mdw314.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 202.85 kB
Formato Adobe PDF
202.85 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/442266
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 41
social impact